 weekly cisplatin-based induction regimen extensive non-small cell lung cancer Southwest Oncology Group study purpose Phase II pilot study dose-intensive regimen weekly cisplatin active non-cross-resistant agents response rate survival time patients extensive non-small cell lung cancer Patients cisplatin days mitomycin days vinblastine days continuous infusion hours days patients consolidation therapy cisplatin etoposide registered patients eligible evaluable response overall response rate patient complete response CR patients partial response PR median survival time months toxicity profile different standard-dose regimens regimen benefit standard-dose cisplatin regimens patients extensive non-small lung cancer weekly schedule dose-intensive regimen acceptable toxicity tumors approach